Latest release supports the use of MS-based purity assays from R&D through to regulated environments
BASEL, Switzerland, April 23, 2025 /PRNewswire-PRWeb/ -- Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced the latest release of Genedata Expressionist®, the industry-leading platform for streamlining and automating the characterization and quality monitoring of biotherapeutics using Mass Spectrometry (MS). Genedata Expressionist 2025.1 extends characterization of synthetic oligonucleotides and mRNA-based therapeutics and revolutionizes the overall efficiency and reliability of the Multi-Attribute Method (MAM) by introducing a novel New Peak Detection (NPD) workflow.
The most significant challenge for NPD data analysis is identifying and differentiating true signals within complex spectra from false positives, which usually requires time-consuming manual review by experts. Genedata Expressionist addresses this challenge by introducing an algorithm that not only detects and reduces false positives but also enables routine analysis in QC settings by non-MS experts.
Developed in close collaboration with industry-leading partners, the robust, efficient, and user-friendly NPD workflow in Genedata Expressionist leverages automatic artifact detection and a sequential filtering strategy to practically eliminate false positives across large datasets. Automated workflows detect new, changing, and absent species with unmatched precision and speed, while intuitive visualizations provide users with a complete analysis overview and facilitate result evaluation for non-MS experts.
"The ability to rely on a fully integrated and automated MAM NPD workflow is a game changer and should facilitate the rapid acceptance of MAM in QC," said Othmar Pfannes, Ph.D., President of Genedata. "With Genedata Expressionist, organizations can now make informed decisions across the global biopharma network, from R&D to regulated environments, based on in-depth product and process understanding."
Moreover, this release continues Genedata's commitment to supporting all modalities, including oligonucleotides. Genedata Expressionist consolidates its leading position in intact mass capabilities for impurity analysis and introduces identification based on MS/MS fragment spectra mapping, which is essential for detecting sequence variants and chemical modifications during oligonucleotide synthesis. Additionally, the configuration of a master library simplifies the selection of modifications that would otherwise need to be individually created. Finally, for natural, long oligonucleotides such as mRNA, Genedata Expressionist enables automatic generation of candidates for poly(A)-tail sequence analysis.
Trusted by leading biopharmaceutical companies worldwide, Genedata Expressionist continues to streamline biopharma workflows across organizations to deliver high-quality results with significant time and cost savings due to automating and harmonizing all MS data processes.
About Genedata
Genedata transforms data into intelligence with innovative software solutions that incorporate extensive biopharma R&D domain knowledge. Multinational biopharmaceutical organizations and cutting-edge biotechs around the globe rely on Genedata to digitalize and automate data-rich and complex R&D processes. From early discovery all the way to the clinic, Genedata solutions help maximize the ROI in R&D expenditure. Founded in 1997, Genedata is headquartered in Basel, Switzerland with additional offices in Boston, London, Munich, San Francisco, Singapore, and Tokyo.
http://www.genedata.com
LinkedIn | X | YouTube
Contact
Allison Kurz
Genedata
Public Relations
[email protected]
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.
Media Contact
Allison Kurz, Genedata, +41 61 511 84 00, [email protected], www.genedata.com
SOURCE Genedata
Share this article